Ankrin Therapeutics ApS: Financial statements 2022
CVR: 39788705
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Ankrin Therapeutics ApS (CVR 39788705) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -1,024,945 and a net result of DKK -2,732,702 compared with DKK -4,493,439 the year before. Equity in the 2022 report amounted to DKK -4,445,020. The company had 2 employees in the financial year.
- Gross Profit
- DKK -1,024,945
- Profit/Loss
- DKK -2,732,702
- Equity
- DKK -4,445,020
- Total Assets
- DKK 3,656,235
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -1 mio. | -2.7 mio. | -4.4 mio. | 2 |
| 2021 | - | -2.4 mio. | -4.5 mio. | -1.7 mio. | 3 |
| 2020 | - | -2.1 mio. | -3.5 mio. | 2.8 mio. | 2 |
Official annual report
Keep an eye on Ankrin Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Ankrin Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -2,427,405, and the net result was DKK -4,493,439.
About Ankrin Therapeutics ApS
Ankrin Therapeutics ApS was a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2018. The company has been dissolved on 5 December 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Ankrin Therapeutics IvS. The company has 4 employees (2024). In 2023, the company reported a gross profit of DKK -497,960 and a net result of DKK -2,334,458 compared with DKK -2,732,702 the year before. Equity in the 2023 report amounted to DKK -6,779,478.